	US 12,312,617 B2
	Cell wall hydrolases targeting c. acnes
Jennifer Shock, San Francisco, CA (US); Maritza Miller, Oakland, CA (US); Oliver Liu, San Francisco, CA (US); and Teresa Shock, San Francisco, CA (US)
Assigned to Topaz Biosciences, Inc., Emeryville, CA (US)
Filed by Topaz Biosciences, Inc., Emeryville, CA (US)
Filed on Sep. 11, 2024, as Appl. No. 18/882,341.
Application 18/882,341 is a continuation of application No. PCT/US2024/039933, filed on Jul. 26, 2024.
Claims priority of provisional application 63/529,224, filed on Jul. 27, 2023.
Prior Publication US 2025/0034537 A1, Jan. 30, 2025
Int. Cl. C12N 9/00 (2006.01); A61K 9/00 (2006.01); A61K 38/47 (2006.01); A61P 17/10 (2006.01); C12N 9/24 (2006.01)

CPC C12N 9/2402 (2013.01) [A61K 9/0014 (2013.01); A61K 38/47 (2013.01); A61P 17/10 (2018.01); C12Y 302/01017 (2013.01)]

25 Claims

1. A chimeric cell wall hydrolase (CWH) comprising the fusion of:

a) a CLC1-family enzymatically active domain (EAD), said EAD having at least 95% sequence identity to SEQ ID NO: 2939; and

b) a heterologous cell well binding domain (CBD),

wherein the chimeric CWH exhibits lytic activity against Cutibacterium acnes.